In particular, the use of mass spectrometry on immunopurified light chains from patients’ serum has identified distinctive M protein mass distributions patterns possibly indicating N-glycosylation of monoclonal light chains in 33 and 10.2% of patients with AL-κ and AL-λ amyloidosis, compared to 3.7 and 4.9% in patients with non-AL monoclonal gammopathies of κ and λ type, respectively (Kumar et al., 2019). Here, MYOM2 is linked to axial length measurement.